Search research articles
Contact Us
Filters
Showing results (101-110 of 148) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
D Trapani, M A Franzoi, H J Burstein, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Current Medical Research and Opinion
|
March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
R Wuerstlein, K Sotlar, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
ESMO Open
|
November 22, 2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
G Zhang, H Ni, L Mishieva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H S Rugo, V Diéras, K A Gelmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
O Gluz, C Liedtke, J Huober, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial
M Untch, H Eidtmann, A du Bois, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 148) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
D Trapani, M A Franzoi, H J Burstein, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2024
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
L Pusztai, C Denkert, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2018
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D A Yardley, R Coleman, P Conte, et al.
Current Medical Research and Opinion
|
March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
R Wuerstlein, K Sotlar, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
ESMO Open
|
November 22, 2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
G Zhang, H Ni, L Mishieva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H S Rugo, V Diéras, K A Gelmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
O Gluz, C Liedtke, J Huober, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial
M Untch, H Eidtmann, A du Bois, et al.
Page
of 15